Compounds > bms 665053
Page last updated: 2024-11-13

bms 665053

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BMS 665053: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44194975
CHEMBL ID562219
MeSH IDM0544474

Synonyms (8)

Synonym
bms-665053
CHEMBL562219 ,
bdbm50293910
(s)-5-chloro-1-(1-cyclopropylethyl)-3-(2,6-dichloro-4-(difluoromethoxy)phenylamino)pyrazin-2(1h)-one
1173435-64-7
bms 665053
bms-665053, >=98% (hplc)
AKOS040748012

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal."( In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Ahuja, VT; Arvanitis, AG; Brenner, AB; Bronson, JJ; Combs, AP; Denhart, DJ; Deskus, JA; Ditta, JL; Grace, JE; Hartz, RA; Lelas, S; Lentz, KA; Li, J; Li, YW; Lodge, NJ; Macor, JE; Mattson, RJ; Molski, TF; Olson, RE; Rafalski, M; Schmitz, WD; Wong, H; Yue, EW; Zaczek, R, 2009)		0.35

Bioavailability

ExcerptReferenceRelevance
"0 nM) and selective CRF(1) receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats."( In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Ahuja, VT; Arvanitis, AG; Brenner, AB; Bronson, JJ; Combs, AP; Denhart, DJ; Deskus, JA; Ditta, JL; Grace, JE; Hartz, RA; Lelas, S; Lentz, KA; Li, J; Li, YW; Lodge, NJ; Macor, JE; Mattson, RJ; Molski, TF; Olson, RE; Rafalski, M; Schmitz, WD; Wong, H; Yue, EW; Zaczek, R, 2009)		0.35
"A series of phosphate and ester-based prodrugs of anilinopyrazinone 1 (BMS-665053) containing either a methylene or an (acyloxy)alkoxy linker was prepared and evaluated in rat pharmacokinetic studies with the goal of improving the oral bioavailability of the parent (1)."( Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF
Ahuja, VT; Bronson, JJ; Grace, JE; Hartz, RA; Lodge, NJ; Macor, JE; Vrudhula, VM, 2017)		0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Corticotropin-releasing factor receptor 1Homo sapiens (human)IC50 (µMol)0.00490.00070.06490.3400AID421378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
immune responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
activation of adenylate cyclase activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
female pregnancyCorticotropin-releasing factor receptor 1Homo sapiens (human)
parturitionCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adrenal gland developmentCorticotropin-releasing factor receptor 1Homo sapiens (human)
exploration behaviorCorticotropin-releasing factor receptor 1Homo sapiens (human)
fear responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
behavioral response to ethanolCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
general adaptation syndrome, behavioral processCorticotropin-releasing factor receptor 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 1Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of corticosterone secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
neuron projectionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID421361Cmax in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous solution of oleoyl macrogolglyceride/DMAC/polysorbate 80, 85:10:5 within 0.25 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421371Plasma free concentration in Sprague-Dawley rat at 1 mg/kg, po2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421369Plasma free concentration in Sprague-Dawley rat at 10 mg/kg, po2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID442811Metabolic stability in NADPH-fortified human liver microsomes assessed as pyrazinone oxidation metabolite formation at 10 uM after 30 mins by HPLC/UV/MS analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
AID421365Fraction unbound in Sprague-Dawley rat plasma at 10 mg/kg, po after 3 hrs by equilibrium dialysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421379Agonist activity at CRF1 receptor in human Y-79 cells assessed as potentiation of CRF-induced cAMP production up to 10 uM after 30 mins by HTRF analysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421363Aqueous solubility at pH 12009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID1432696Thermodynamic equilibrium aqueous solubility in pH 6.5 solution at 1 mg/ml after 15 to 24 hrs by UV-HPLC method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF
AID421378Antagonist activity at CRF1 receptor in human Y-79 cells assessed as inhibition of CRF-induced cAMP production after 30 mins by HTRF analysis2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421353Clearance in Sprague-Dawley rat 2 mg/kg, iv within 0.17 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421381Ex vivo receptor occupancy of CRF1 receptor in po dosed Sprague-Dawley rat brain after 20 mins by autoradiography2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421357AUC in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous suspension of 1% polysorbate 80 in 0.5% methylcellulose within 0.25 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421356Displacement of [125I]ovine-CRF from CRF1 receptor in rat frontal cortex by rapid filtration technique2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID442813Metabolic stability in NADPH-fortified rat liver microsomes assessed as parent compound remaining at 10 uM after 30 mins by HPLC/UV/MS analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
AID421364Aqueous solubility at pH 6.52009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421359Oral bioavailability in Sprague-Dawley rat at 10 mg/kg dosed as aqueous suspension of 1% polysorbate 80 in 0.5% methylcellulose within 0.25 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID442812Metabolic stability in NADPH-fortified human liver microsomes assessed as GSH adduct formation at 10 uM after 30 mins by HPLC/UV/MS analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
AID442810Metabolic stability in NADPH-fortified human liver microsomes assessed as parent compound remaining at 10 uM after 30 mins by HPLC/UV/MS analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
AID421367Total plasma concentration in Sprague-Dawley rat at 3 mg/kg, po2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421352Volume of distribution at steady state in Sprague-Dawley rat 2 mg/kg, iv within 0.17 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421354Hepatic blood flow in Sprague-Dawley rat 2 mg/kg, iv2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID701834Drug metabolism in rat liver microsomes assessed as GSH adduct formation at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Mitigating heterocycle metabolism in drug discovery.
AID442815Metabolic stability in NADPH-fortified rat liver microsomes assessed as GSH adduct formation at 10 uM after 30 mins by HPLC/UV/MS analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
AID421380Displacement of [125I]sauvagine from CRF2 receptor in pig choroid plexus by rapid filtration technique2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID1432699Oral bioavailability in Sprague-Dawley rat at 10 mg/kg by LC-MS/MS analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF
AID1432695Thermodynamic equilibrium aqueous solubility in pH 1 solution at 1 mg/ml after 15 to 24 hrs by UV-HPLC method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF
AID421377Anxiolytic activity in Sprague-Dawley rat at 1 mg/kg, po assessed as decrease in exit latency after 60 mins by defensive withdrawal test relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID701835Drug metabolism in rat liver microsomes at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Mitigating heterocycle metabolism in drug discovery.
AID421360AUC in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous solution of oleoyl macrogolglyceride/DMAC/polysorbate 80, 85:10:5 within 0.25 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421368Total plasma concentration in Sprague-Dawley rat at 1 mg/kg, po2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421375Anxiolytic activity in Sprague-Dawley rat at 10 mg/kg, po assessed as decrease in exit latency after 60 mins by defensive withdrawal test relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421370Plasma free concentration in Sprague-Dawley rat at 3 mg/kg, po2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421376Anxiolytic activity in Sprague-Dawley rat at 3 mg/kg, po assessed as decrease in exit latency after 60 mins by defensive withdrawal test relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421362Oral bioavailability in Sprague-Dawley rat at 10 mg/kg dosed as aqueous solution of oleoyl macrogolglyceride/DMAC/polysorbate 80, 85:10:5 within 0.25 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421374Ex vivo receptor occupancy of CRF1 receptor in Sprague-Dawley rat brain at 1 mg/kg, po after 20 mins by autoradiography relative to [125I-tyrosine]sauvagine2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID1432697AUC (0 to 24 hrs) in Sprague-Dawley rat at 10 mg/kg, po by LC-MS/MS analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF
AID421358Cmax in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous suspension of 1% polysorbate 80 in 0.5% methylcellulose within 0.25 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421355Intrinsic clearance in human liver microsomes at 1 uM2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421351Half life in Sprague-Dawley rat 2 mg/kg, iv within 0.17 to 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421372Ex vivo receptor occupancy of CRF1 receptor in Sprague-Dawley rat brain at 10 mg/kg, po after 20 mins by autoradiography relative to [125I-tyrosine]sauvagine2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID421366Total plasma concentration in Sprague-Dawley rat at 10 mg/kg, po2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID1432698Cmax in Sprague-Dawley rat at 10 mg/kg, po by LC-MS/MS analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF
AID421373Ex vivo receptor occupancy of CRF1 receptor in Sprague-Dawley rat brain at 3 mg/kg, po after 20 mins by autoradiography relative to [125I-tyrosine]sauvagine2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
AID442814Metabolic stability in NADPH-fortified rat liver microsomes assessed as pyrazinone oxidation metabolite formation at 10 uM after 30 mins by HPLC/UV/MS analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		3.1710imidazole
pyrazole
1H-pyrazole : The 1H-tautomer of pyrazole.		3.1710pyrazole
pyridine
azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.		3.1710azaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines		environmental contaminant;
NMR chemical shift reference compound
piperazine
[no description available]		3.1710azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.1710pyrrole;
secondary amine
piperidine
[no description available]		3.1710azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine		base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent
morpholine
[no description available]		3.1710morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound
hexahydroazepine
hexahydroazepine: RN given refers to parent cpd. azepane : An azacycloalkane that is cycloheptane in which one of the carbon atoms is replaced by a nitrogen atom.		3.1710azacycloalkane;
azepanes;
saturated organic heteromonocyclic parent
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		3.1710isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		3.17101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		3.17101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
1,2,4-triazole
1,2,4-triazole: RN given refers to 1H-1,2,4-triazole		3.17101,2,4-triazole
pyridazine
pyridazine: structure given in first source		3.1710diazine;
pyridazines
pyrimidine
pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.		3.1710diazine;
pyrimidines		Daphnia magna metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		3.8730diazine;
pyrazines		Daphnia magna metabolite
azetidine
[no description available]		3.1710azacycloalkane;
azetidines;
saturated organic heteromonocyclic parent
pyrrolidine
[no description available]		3.1710azacycloalkane;
pyrrolidines;
saturated organic heteromonocyclic parent
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		3.17101,2,3-triazole
1h-tetrazole
tetrazole : An azaarene that is a five-membered ring composed of 4 nitrogen and 1 carbon atom.. 2H-tetrazole : A tetrazole tautomer where the proton is located on the 2 position.		3.1710one-carbon compound;
tetrazole
glucuronic acid
Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.		2.0510D-glucuronic acidalgal metabolite
dmp 696
DMP 696: a CRF(1) receptor antagonist; structure in first source		2.4520
ConditionIndicatedRelationship StrengthStudiesTrials